Fig. 3.

Exercise Enhancement of Proteasome Function. tPVAT samples were measure for proteasome protease activity at all three 20S active sites (A, n=6–8); LLVY (chymotrypsin-like), RLR (trypsin-like) and nLPnLD (caspase-like site). tPVAT samples were analyzed for levels of ubiquitin and the 20S proteasome beta-subunit (B, n=5). Ubiquitin-dependent 26S proteasome substrate degradation was measured in tPVAT samples by a linier ubiquitin chain-GFP substrate (C, n=6–8). Aortic relaxation was assessed in LZR aortic rings incubated with LZR tPVAT pre-treated with the proteasome inhibitor MG132 (D, n=4). Effects of proteasome inhibition in OZR Ex tPVAT on endothelial dependent dilation of healthy (donor) aortas (E, n=4). Data are represented as Mean ± SD. For panels A-C, *p < 0.05, **p < 0.01, ***p < 0.001 compared to LZR or between groups connected by a bar. For panels D and E, **p < 0.01 compared to LZR control tPVAT or OZR Ex tPVAT with MG132.